Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific expects to nearly double Target Therapeutics revenues in 1997, CFO says.

This article was originally published in The Gray Sheet

Executive Summary

BOSTON SCIENTIFIC TO NEARLY DOUBLE TARGET THERAPEUTICS REVENUE to "over $170 mil." in 1997, Chief Financial Officer Larry Best predicted June 17 at the Piper Jaffray investment conference in Minneapolis. BSC expects that its newly acquired minimally invasive neurointerventional division, which generated an estimated $89.2 mil. in sales during fiscal year 1997 (ended March 31) as an independent company, will benefit from an ongoing switch to direct sales in international markets.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT008300

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel